Form 4: Puma Biotechnology Director Jay M. Moyes Sells 22,000 Shares

Director Jay M. Moyes of Puma Biotechnology sold 22,000 shares of common stock on June 13, 2024, at a weighted average price of $3.3394.

Summary

• On June 13, 2024, Jay M. Moyes, a director of Puma Biotechnology, Inc., sold 22,000 shares of common stock.
• The sale was executed under a pre-arranged 10b5-1(c) trading plan adopted on December 17, 2023.
• The shares were sold at a weighted average price of $3.3394, with individual transaction prices ranging from $3.3001 to $3.5401.
• Following the transaction, Moyes directly owns 21,322 shares of Puma Biotechnology.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale by a director under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

Sales by company insiders are a common occurrence and are closely watched by investors for signals about the company's prospects. A pre-planned sale under a 10b5-1 plan is generally viewed as less concerning than discretionary sales.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, although the existence of a pre-arranged trading plan mitigates this concern.

Key Dates